Rooted in Science Sourced Worldwide

A Message to Our Patients

Harnessing innovative scientific discoveries to deliver better medicines to patients

At LianBio, our mission is to bring transformative medicines to historically underserved patients in China and throughout Asia. Our team is determined to accelerate the availability of new, best-in-class medicines in our region, beginning with our pipeline of clinically validated programs.

We invite you to learn more about the various diseases we are targeting and explore the status of our ongoing clinical trials below.

Our Areas of Focus

Hypertrophic Cardiomyopathy (HCM)

HCM is a chronic disease that leads to progressive deterioration of heart function and an increased risk of irregular and rapid heartbeat, stroke, heart failure and sudden cardiac arrest. Currently, there are an estimated 1.1 million patients with HCM in China.

Learn More

Demodex Blepharitis (DB)

DB is a disease characterized by chronic eye inflammation, irritation, and redness. Symptoms can become severe if left untreated, and progress to blurred vision, missing eyelashes, corneal damage and even blindness in extreme cases. There are an estimated 43 million DB patients in China.

Learn More

Cholangiocarcinoma (CCA)

CCA is a highly invasive cancer that originates from bile duct epithelial cells. A number of factors associated with liver damage, such as gallstones, exposure to toxins and hepatitis B and hepatitis C virus infections, increase the risk of developing CCA. Approximately 72,000 patients in China are diagnosed with intrahepatic CCA annually.

Learn More

Gastric Cancers

Gastric cancer develops from the cancerous transformation of cells that line the stomach. Genetic abnormalities involving fibroblast growth factor receptors (FGFR) occur in approximately 7% of cancers, most notably in gastric cancers. Gastric cancer is the second most common type of cancer in China and the third leading cause of cancer-related deaths.

Learn More

Head & Neck Cancer

Head and neck cancers include cancers of the oral cavity, pharynx, larynx, sinuses and nasal cavity, and salivary glands. In China, there are approximately 140,000 newly diagnosed head and neck cancer patients each year.

Learn More

Chronic Rhinosinusitis (CRS)

CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. CRS constitutes a substantial disease burden in Asia, with 88 million cases in Chinese adults ages 18-74 alone, an estimated 3.4 million of whom have failed currently available medical management.

Learn More

Inflammatory bowel disease (IBD)

IBD is a chronic autoimmune inflammatory condition that primarily affects the intestines and colon. Diet and lifestyle are thought to be key drivers of IBD, and IBD produces a variety of signs and symptoms ranging from mild to severe that negatively impact quality of life. It is estimated that there are 590,000 IBD patients in China.

Learn More

Respiratory Syncytial Virus (RSV)

RSV is a respiratory pathogen that can lead to severe and life-threatening lower respiratory tract infections in high-risk populations, including infants, immunocompromised individuals and the elderly. RSV impacts a large patient population, affecting approximately 64 million people and causing approximately 160,000 deaths globally each year. In China, RSV is the leading pathogen causing acute respiratory tract infection particularly in infants and young children.

Learn More

Clinical Trials

Clinical trials are essential to bringing safe and effective medicines to patients.


For the treatment of obstructive hypertrophic cardiomyopathy

Phase 3 EXPLORER-CN trial of mavacamten in symptomatic oHCM is currently recruiting patients.

For more information, please visit:


For the treatment of gastric cancer and other FGFR-driven cancers

Phase 2a trial of infigratinib in gastric cancer and other advanced solid tumors is currently recruiting patients.

For more information, please visit:

If you are interested in participating in clinical research for one of our focus areas, please speak with your physician.